Poster presentation to feature data highlighting Kalohexis’ novel approach to melanocortin agonism and its oral MC3R/MC4R dual agonist, 710GO, in obese mice Northbrook, Ill., October 7, 2026 /PRNewswire/ — Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today…
Experienced life sciences entrepreneur, executive, and investor brings extensive company-building, capital markets, data science and artificial intelligence (AI), and public-company experience Northbrook, Ill., September 22, 2026 /PRNewswire/ — Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the appointment…
Dr. Menzel brings over 30 years of global healthcare executive leadership with broad experience in building successful companies Northbrook, Ill., September 1, 2026 /PRNewswire/ — Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the appointment of…
Dr. Sherman, former CMO of Horizon Therapeutics, brings over 35 years of R&D and regulatory expertise Northbrook, Ill., August 11, 2026 /PRNewswire/ — Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the appointment of Jeffrey Sherman, MD,…
710GO, Kalohexis’ novel oral dual MC3R/MC4R agonist, is currently being evaluated in a Phase 1 clinical trial as a potentially healthier and more durable treatment for general obesity Northbrook, Ill., July 15, 2026 /PRNewswire/ — Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with…
Northbrook, Ill., July 7, 2026 /PRNewswire/ — Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the confidential submission of a draft Registration Statement on Form S-1 to the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its…
Northbrook, Ill., June 18, 2026 /PRNewswire/ — Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the appointment of Xuan Hui, B.Med., M.S., Ph.D., as Director of Corporate Strategy. Dr. Hui joins Kalohexis from Bank of America Securities,…
Data featured in oral presentation at ENDO 2026 show that dual MC3R/MC4R activation drives weight loss, limits rebound, and preserves lean mass in obese nonhuman primates 710GO, Kalohexis’ novel oral dual MC3R/MC4R agonist, is currently being evaluated in a Phase 1 clinical trial as a treatment for general obesity Northbrook, Ill., June 15, 2026 /PRNewswire/ —…
Dual Activation of MC3R and MC4R Drives Weight Loss and Reduces Food Intake in Male Primates with Obesity Northbrook, Ill., May 29, 2026 /PRNewswire/ — Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced a publication in Nature Communications…
710GO is a next-generation, first-in-class oral dual MC3R/MC4R agonist designed to activate the melanocortin system to induce healthier, more durable weight loss Northbrook, Ill., May 28, 2026 /PRNewswire/ — Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced…